Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Fradet, Y., Bellmunt, J., Vaughn, D.J., Lee, J.L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Nam, K., Frenkl, T.L., Perini, R.F., de Wit, R., Bajorin, D.F.
Published in Annals of oncology (01.06.2019)
Published in Annals of oncology (01.06.2019)
Get full text
Journal Article
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
Choueiri, T.K., Motzer, R.J., Rini, B.I., Haanen, J., Campbell, M.T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J.L., Grimm, M.-O., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M.B., Pal, S.K., Wang, J., Mariani, M., Krishnaswami, S., Cislo, P., Chudnovsky, A., Fowst, C., Huang, B., di Pietro, A., Albiges, L.
Published in Annals of oncology (01.08.2020)
Published in Annals of oncology (01.08.2020)
Get full text
Journal Article
Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial
Chi, K.N., Sandhu, S., Smith, M.R., Attard, G., Saad, M., Olmos, D., Castro, E., Roubaud, G., Pereira de Santana Gomes, A.J., Small, E.J., Rathkopf, D.E., Gurney, H., Jung, W., Mason, G.E., Dibaj, S., Wu, D., Diorio, B., Urtishak, K., del Corral, A., Francis, P., Kim, W., Efstathiou, E.
Published in Annals of oncology (01.09.2023)
Published in Annals of oncology (01.09.2023)
Get full text
Journal Article
Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
Lin, H-M, Castillo, L, Mahon, K L, Chiam, K, Lee, B Y, Nguyen, Q, Boyer, M J, Stockler, M R, Pavlakis, N, Marx, G, Mallesara, G, Gurney, H, Clark, S J, Swarbrick, A, Daly, R J, Horvath, L G
Published in British journal of cancer (13.05.2014)
Published in British journal of cancer (13.05.2014)
Get full text
Journal Article
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
Tannir, N.M., Albigès, L., McDermott, D.F., Burotto, M., Choueiri, T.K., Hammers, H.J., Barthélémy, P., Plimack, E.R., Porta, C., George, S., Donskov, F., Atkins, M.B., Gurney, H., Kollmannsberger, C.K., Grimm, M.-O., Barrios, C., Tomita, Y., Castellano, D., Grünwald, V., Rini, B.I., Jiang, R., Desilva, H., Fedorov, V., Lee, C.-W., Motzer, R.J.
Published in Annals of oncology (01.11.2024)
Published in Annals of oncology (01.11.2024)
Get full text
Journal Article
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma
Agarwal, N., Brugarolas, J., Ghatalia, P., George, S., Haanen, J.B., Gurney, H., Ravilla, R., Van der Veldt, A., Beuselinck, B., Pokataev, I., Suelmann, B.B.M., Tuthill, M.H., Vaena, D., Zagouri, F., Wu, J., Perini, R.F., Liu, Y., Merchan, J., Atkins, M.B.
Published in Annals of oncology (02.09.2024)
Published in Annals of oncology (02.09.2024)
Get full text
Journal Article
Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662
Diekstra, M H M, Klümpen, H J, Lolkema, M P J K, Yu, H, Kloth, J S L, Gelderblom, H, van Schaik, R H N, Gurney, H, Swen, J J, Huitema, A D R, Steeghs, N, Mathijssen, R H J
Published in Clinical pharmacology and therapeutics (01.07.2014)
Published in Clinical pharmacology and therapeutics (01.07.2014)
Get more information
Journal Article
Metformin in prostate cancer: two for the price of one
Clements, A., Gao, B., Yeap, S.H.O., Wong, M.K.Y., Ali, S.S., Gurney, H.
Published in Annals of oncology (01.12.2011)
Published in Annals of oncology (01.12.2011)
Get full text
Journal Article
Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer
Mahon, K L, Qu, W, Devaney, J, Paul, C, Castillo, L, Wykes, R J, Chatfield, M D, Boyer, M J, Stockler, M R, Marx, G, Gurney, H, Mallesara, G, Molloy, P L, Horvath, L G, Clark, S J
Published in British journal of cancer (28.10.2014)
Published in British journal of cancer (28.10.2014)
Get full text
Journal Article
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer
Sternberg, C.N., Saad, F., Graff, J.N., Peer, A., Vaishampayan, U.N., Leung, E., Rosenbaum, E., Gurney, H., Epstein, R.J., Davis, I.D., Wu, B., Trandafir, L., Wagner, V.J., Hussain, M.
Published in Annals of oncology (01.02.2020)
Published in Annals of oncology (01.02.2020)
Get full text
Journal Article
The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer
Barbour, Andrew P., Samra, Jaswinder S., Haghighi, Koroush S., Donoghoe, Mark W., Burge, Matthew, Harris, Marion T., Chua, Yu Jo, Mitchell, Jenna, O’Rourke, Nick, Chan, Howard, Gebski, Val J., Gananadha, Sivakumar, Croagh, Daniel G., Kench, James G., Goldstein, David
Published in Annals of surgical oncology (01.07.2020)
Published in Annals of surgical oncology (01.07.2020)
Get full text
Journal Article
Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics
Nath, C. E., Trotman, J., Nivison-Smith, I., Gurney, H., Zeng, L., Presgrave, P., Tiley, C., Joshua, D., Kerridge, I., McLachlan, A. J., Shaw, P. J.
Published in Bone marrow transplantation (Basingstoke) (01.09.2020)
Published in Bone marrow transplantation (Basingstoke) (01.09.2020)
Get full text
Journal Article
JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
Motzer, R.J., Penkov, K., Haanen, J.B.A.G., Rini, B.I., Albiges, L., Campbell, M.T., Kollmannsberger, C.K., Negrier, S., Uemura, M., Lee, J.L., Gurney, H., Berger, R., Schmidinger, M., Larkin, J., Atkins, M.B., Wang, J., Robbins, P.B., Chudnovsky, A., Di Pietro, A., Choueiri, T.K.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype
Gurney, H, Wong, M, Balleine, R L, Rivory, L P, McLachlan, A J, Hoskins, J M, Wilcken, N, Clarke, C L, Mann, G J, Collins, M, Delforce, S-E, Lynch, K, Schran, H
Published in Clinical pharmacology and therapeutics (01.07.2007)
Published in Clinical pharmacology and therapeutics (01.07.2007)
Get more information
Journal Article
711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
Albiges, L., Tannir, N., Burotto, M., McDermott, D.F., Plimack, E.R., Barthélémy, P., Porta, C.G., Powles, T.B., Donskov, F., George, S., Kollmannsberger, C., Gurney, H., Grimm, M-O., Tomita, Y., Castellano Gauna, D., Rini, B.I., Choueiri, T.K., Saggi, S.S., McHenry, M.B., Motzer, R.J.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
Environmental and genetic factors affecting transport of imatinib by OATP1A2
Eechoute, K, Franke, R M, Loos, W J, Scherkenbach, L A, Boere, I, Verweij, J, Gurney, H, Kim, R B, Tirona, R G, Mathijssen, R H J, Sparreboom, A
Published in Clinical pharmacology and therapeutics (01.06.2011)
Published in Clinical pharmacology and therapeutics (01.06.2011)
Get more information
Journal Article
Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis
McDermott, D.F., Rini, B.I., Motzer, R.J., Tannir, N.M., Escudier, B., Kollmannsberger, C.K., Hammers, H.J., Porta, C., George, S., Donskov, F., Gurney, H.P., Grimm, M.-O., Harrison, M., Hutson, T.E., Doan, J., Yang, S., Rao, S., Mekan, S., Ambavane, A., Powles, T.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
Powles, T., Burotto, M., Escudier, B., Apolo, A.B., Bourlon, M.T., Shah, A.Y., Suárez, C., Porta, C., Barrios, C.H., Richardet, M., Gurney, H., Kessler, E.R., Tomita, Y., Bedke, J., George, S., Scheffold, C., Wang, P., Fedorov, V., Motzer, R.J., Choueiri, T.K.
Published in ESMO open (01.05.2024)
Published in ESMO open (01.05.2024)
Get full text
Journal Article